A “connected by intent” approach is key to harnessing the benefits of IT-OT convergence
In recent years, the biopharmaceutical market has grown at an astonishing rate. This is evidenced by a surge in mergers and acquisitions and is underpinned by the emergence of cutting-edge technologies such as gene editing and personalised medicine